BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma. World J Hepatol 2014; 6(12): 836-843 [PMID: 25544870 DOI: 10.4254/wjh.v6.i12.836] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
2 Wang W, Zhang H, Tang M, Liu L, Zhou Z, Zhang S, Wang L. MicroRNA-592 targets IGF-1R to suppress cellular proliferation, migration and invasion in hepatocellular carcinoma. Oncol Lett. 2017;13:3522-3528. [PMID: 28529580 DOI: 10.3892/ol.2017.5902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Ding Q, He D, He K, Zhang Q, Tang M, Dai J, Lv H, Wang X, Xiang G, Yu H. Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers. Tumour Biol 2015;36:8761-72. [PMID: 26055142 DOI: 10.1007/s13277-015-3572-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
4 Li M, Wang Z, Cao J, Han B, Zou H, Zang Y, Wu L. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. European Journal of Surgical Oncology 2019;45:1684-90. [DOI: 10.1016/j.ejso.2019.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Matsuno Y, Yamazaki S, Mitsuka Y, Abe H, Moriguchi M, Higaki T, Takayama T. Subcuticular Sutures Versus Staples for Wound Closure in Open Liver Resection: A Randomised Clinical Trial. World J Surg 2021;45:571-80. [PMID: 33104835 DOI: 10.1007/s00268-020-05833-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhang XL, Wang WJ, Wang WJ, Cao N. Effectiveness and safety of controlled venous pressure in liver surgery: a systematic review and network meta-analysis. Biomed Res Int 2015;2015:290234. [PMID: 26075222 DOI: 10.1155/2015/290234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
7 Ochiai T, Inoue H, Watanabe N, Ito H, Toma A, Morimura R, Ikoma H, Otsuji E. Outcome of a second hepatectomy in octogenarians with hepatocellular carcinoma recurrence: single centre's experience. ANZ J Surg 2019;89:1270-4. [PMID: 31280497 DOI: 10.1111/ans.15330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Chen ZH, Feng JK, Sun JX, Wu JY, Guo WX, Shi J, Wei YG, Zhou JY, Zhang ZB, Yan ML, Cheng SQ. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. HPB (Oxford) 2021:S1365-182X(21)01625-7. [PMID: 34635434 DOI: 10.1016/j.hpb.2021.09.005] [Reference Citation Analysis]
9 Yu S, Bo T, Hou B, Li J, Zhou X. Surgery strategy of 13 cases to control bleeding from the liver on laparoscopic repeat liver resection for recurrent hepatocellular carcinoma. J Minim Access Surg 2019;15:214-8. [PMID: 29794359 DOI: 10.4103/jmas.JMAS_214_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Lai HC, Yeh CC, Jeng LB, Huang SF, Liao PY, Lei FJ, Cheng WC, Hsu CL, Cai X, Chang C, Ma WL. Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. Oncotarget 2016;7:46448-65. [PMID: 27340775 DOI: 10.18632/oncotarget.10186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Li G, Yang F, Xu H, Yue Z, Fang X, Liu J. MicroRNA-708 is downregulated in hepatocellular carcinoma and suppresses tumor invasion and migration. Biomedicine & Pharmacotherapy 2015;73:154-9. [DOI: 10.1016/j.biopha.2015.05.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
12 Wang Y, He D, Yang L, Wen B, Dai J, Zhang Q, Kang J, He W, Ding Q, He D. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun 2015;463:458-65. [PMID: 26043685 DOI: 10.1016/j.bbrc.2015.05.117] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]